Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance.

Yiping Huang,Jun Seop Jeong,Jun Okamura,Myoung Sook-Kim,Heng Zhu,Rafael Guerrero-Preston,Edward A Ratovitski

DOI: https://doi.org/10.4161/cc.20863

2012-01-01

Cell Cycle

Abstract:Cisplatin chemoresistance is a clinical problem that leads to treatment failure in various human epithelial cancers. Members of tumor protein (TP) p53 family play various critical roles in the multiple molecular mechanisms underlying the chemoresistance of tumor cells. However, the in-depth mechanisms of the cellular response to cisplatin-induced cell death are still under thorough investigation. We previously showed that squamous cell carcinoma (SCC) cells exposed to cisplatin display an ATM-dependent phosphorylation of Delta Np63 alpha, leading to a specific function of the phosphorylated (p)-Delta Np63 alpha transcription factor in cisplatin-sensitive tumor cells. We further found that SCC cells expressing non-p-Delta Np63 alpha-S385G became cisplatin-resistant. Using quantitative mass spectrometry of protein complexes labeled with isobaric tags, we showed that Tp53 and Delta Np63 alpha are involved in numerous protein-protein interactions, which are likely to be implicated in the response of tumor cells to cisplatin exposure. We found that p-Delta Np63 alpha binds to the splicing complex, leading to repression of mRNA splicing and activation of ACIN1-mediated cell death pathway. In contrast to p-Delta Np63 alpha, non-p-Delta Np63 alpha fails to bind the critical members of the splicing complex, thereby leading to activation of RNA splicing and reduction of cell death pathway. Overall, our studies provide an integrated proteomic platform in making a case for the role of the p53/p63 interactome in cisplatin chemoresistance.